Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suclear is an osmotic laxative kit developed by Braintree Laboratories (a subsidiary of Sebela Pharmaceuticals) for bowel cleansing in preparation for colonoscopy in adults. The product is supplied as a co-packaged kit containing two components: a 6-ounce bottle of oral solution consisting of sodium sulfate, potassium sulfate, and magnesium sulfate, and a 2-liter jug containing powder for oral solution consisting of polyethylene glycol 3350 (PEG-3350), sodium chloride, sodium bicarbonate, and potassium chloride. The mechanism of action is primarily physical; the sulfate salts and PEG-3350 are poorly absorbed and exert an osmotic effect, retaining water within the intestinal lumen. This results in a copious watery diarrhea that effectively cleanses the colon to allow for clear visualization during endoscopic procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suclear.